iShares Managed Futures Active ETF (ISMF)
Live price chart, market sentiment, and community perspectives for iShares Managed Futures Active ETF (CBOE: ISMF).
Live price chart, market sentiment, and community perspectives for iShares Managed Futures Active ETF (CBOE: ISMF).
On our desk, we noticed that BlackRock is taking a page straight from the hedge fund playbook by bringing active managed futures into an ETF wrapper with ISMF. Seeing 11 funds open new positions and 4 increase them in Q1 2026 for a total of $41.8M tells me institutional allocators are looking seriously at differentiated return sources across equities, interest rates, commodities, and currencies.
From a risk management standpoint, ISMF's 1-year NAV return of 20.91% looks impressive compared to its benchmark's 3.84%, but we have to watch the liquidity constraints. With a 10-day average volume floating around 0.01M shares and a net expense ratio of 0.80%, execution slippage could eat into those active gains if wider market volatility strikes suddenly.
As a quant analyst reviewing Morningstar's risk metrics for ISMF, I note the standard deviation sits at 10.16 relative to its category peers. Even though it operates as an active systematic trend ETF tracking no index, investors must weigh the 0.82% gross expense ratio against the realized volatility and the broader macro environment where both stocks and bonds face intermittent pressure.
Watching the 52-week range between $24.23 and $30.72 on CNBC, it is clear ISMF has experienced notable swings since its 2025 launch. Institutional buyers like AG AlTi Global and EFG Financial Group stepping in with meaningful capital flows during Q1 2026 suggest that wealth managers are actively hunting for uncorrelated alternatives as traditional stock-bond correlations wobble.
When evaluating systematic trend funds like ISMF for our asset allocation framework, I pay close attention to the mandate: long and short futures exposure across four distinct asset classes without leverage. The fact that the 30-day SEC yield sits at 2.52% provides a small income buffer, but the core thesis relies strictly on capturing macro trends as demonstrated by its strong trailing performance since its March 2025 inception.
Explore plasma cleansing, somatic organ swaps, and BCI.